TD Cowen analyst Yaron Werber has maintained their bullish stance on ZYME stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yaron Werber has given his Buy rating due to a combination of factors that highlight Zymeworks’ strong performance and future potential. The company reported a solid third quarter, with revenues exceeding expectations, largely driven by milestone payments and royalties. Zymeworks’ focus on the upcoming data release for the HERIZON-GEA-01 trial in first-line HER2+ gastric and esophageal adenocarcinoma (GEA) is a significant catalyst, as positive results are anticipated to greatly expand market opportunities.
Additionally, Zymeworks’ pipeline is showing promising developments, with ZW191 demonstrating best-in-class potential among FRα ADCs and the first patient dosed in the ZW251 trial for hepatocellular carcinoma (HCC). The company’s cash position is strong, providing a runway into the second half of 2027, which supports continued research and development efforts. These factors, combined with the potential for substantial stock appreciation if trial results meet expectations, underpin Werber’s Buy rating.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $32.00 price target.